{
  "trial_id": "NCT00189163",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "chronic viral hepatitis",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "steatosis and steatohepatitis",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "histological severity of chronic hepatitis C",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "insulin sensitivity",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "hepatitis C patients who underwent previous therapy for their liver disease",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "genotype other than type 1",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "notes": "Patient has chronic viral hepatitis and steatosis and steatohepatitis. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months.",
  "_meta": {
    "topic_id": "27",
    "trial_id": "NCT00189163",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}